Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Blood
Emily Curran, Wendy Stock

Abstract

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.

References

Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah A ThomasHagop M Kantarjian
Mar 24, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Dec 22, 2012·Blood·Renato Bassan
Apr 18, 2014·Blood·Kheira BeldjordUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Sep 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Donna PrzepiorkaRichard Pazdur
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Sep 15, 2016·The New England Journal of Medicine·Sébastien MauryUNKNOWN for GRAALL
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arend von StackelbergLia Gore
Jan 8, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Olga Sala TorraJerald P Radich
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Mar 14, 2019·International Journal of Hematologic Oncology·Larisa BroglieMichael J Burke

❮ Previous
Next ❯

Citations

Apr 23, 2020·American Society of Clinical Oncology Educational Book·Jennifer L McNeerMaureen M O'Brien
Sep 1, 2019·International Journal of Molecular Sciences·Peter ValentDominik Wolf
Dec 7, 2019·Hematology·Jacqueline CloosRichard Dillon
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophia KhaldoyanidiMarion Subklewe
Dec 17, 2019·Current Opinion in Biotechnology·Christoph Rader
Mar 3, 2021·Science Translational Medicine·Suman PaulBert Vogelstein
Aug 12, 2021·Molecular Cancer Therapeutics·Elizabeth PhamJulie M Bailis
Oct 7, 2021·Current Hematologic Malignancy Reports·Ahmed AleemElizabeth A Griffiths

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.